Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Differential expression of the adipocyte amino acid transporter is transactivated by SP1 and SP3 during the 3T3-L1 preadipocyte differentiation process.

Zhu Q., Liao K.

Animal Study, published in Biochem Biophys Res Commun (2000) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biochem Biophys Res Commun (2000)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
10777688
DOI
10.1006/bbrc.2000.2586

Abstract (original English)

It was identified that a Sp1-like cis-element in the adipocyte amino acid transporter gene (AAAT) promoter is the major cis-motif for its induced expression during the 3T3-L1 preadipocyte differentiation process. Electrophoretic mobility shift analysis of this cis DNA element showed that the transcription factors binding to this sequence were Sp1 and Sp3. Protein analysis of Sp1 and Sp3 in nuclear extracts from 3T3-L1 cells at various differentiation stages indicated that these two transcription factors existed in noninduced 3T3-L1 preadipocytes, but they did not bind to the AAAT promoter element with high affinity. They were activated after differentiation induction. It was further demonstrated that dephosphorylation of Sp1 increased its binding affinity to this inducible AAAT promoter element.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
3T3 CellsAdipocytesAmino Acid Transport SystemsAnimalsBlotting, WesternCarrier ProteinsCell DifferentiationCell NucleusDNA-Binding ProteinsMice

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.